Sanctuary Advisors LLC Invests $138,000 in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Sanctuary Advisors LLC acquired a new stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 13,445 shares of the biopharmaceutical company’s stock, valued at approximately $138,000.

Several other hedge funds have also recently made changes to their positions in FOLD. Headlands Technologies LLC purchased a new position in shares of Amicus Therapeutics in the second quarter worth about $89,000. Sage Capital Advisors llc acquired a new position in Amicus Therapeutics in the 2nd quarter worth approximately $103,000. EntryPoint Capital LLC raised its position in Amicus Therapeutics by 278.8% during the 1st quarter. EntryPoint Capital LLC now owns 13,218 shares of the biopharmaceutical company’s stock worth $156,000 after buying an additional 9,729 shares during the last quarter. Xponance Inc. lifted its stake in Amicus Therapeutics by 5.3% during the 2nd quarter. Xponance Inc. now owns 18,555 shares of the biopharmaceutical company’s stock valued at $184,000 after acquiring an additional 936 shares during the period. Finally, SG Americas Securities LLC purchased a new stake in shares of Amicus Therapeutics in the 1st quarter valued at $291,000.

Insider Transactions at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $10.60, for a total transaction of $79,500.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $9,398,532.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders have sold 22,500 shares of company stock valued at $244,875. Corporate insiders own 2.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Bank of America boosted their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, October 17th. Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a research report on Friday, August 9th. JPMorgan Chase & Co. dropped their price objective on shares of Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating on the stock in a research note on Friday, August 16th. Jefferies Financial Group initiated coverage on shares of Amicus Therapeutics in a research note on Friday, September 6th. They issued a “buy” rating and a $18.00 target price for the company. Finally, Morgan Stanley dropped their price target on shares of Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.13.

Amicus Therapeutics Trading Up 0.9 %

FOLD stock opened at $12.01 on Tuesday. Amicus Therapeutics, Inc. has a 12-month low of $9.02 and a 12-month high of $14.57. The business’s 50-day moving average is $11.17 and its 200 day moving average is $10.55. The company has a current ratio of 2.75, a quick ratio of 2.26 and a debt-to-equity ratio of 2.93. The stock has a market cap of $3.56 billion, a price-to-earnings ratio of -24.51 and a beta of 0.69.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.05). The firm had revenue of $126.67 million for the quarter, compared to analyst estimates of $121.21 million. Amicus Therapeutics had a negative return on equity of 41.47% and a negative net margin of 26.23%. The business’s revenue was up 34.0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.15) earnings per share. On average, sell-side analysts anticipate that Amicus Therapeutics, Inc. will post -0.07 EPS for the current fiscal year.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.